These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16468473)

  • 1. Current status of taxanes as adjuvant therapy for early-stage breast cancer.
    Wolff AC
    Int J Fertil Womens Med; 2005; 50(5 Pt 1):227-9. PubMed ID: 16468473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taxanes in the treatment of early breast cancer.
    Ring AE; Ellis PA
    Cancer Treat Rev; 2005 Dec; 31(8):618-27. PubMed ID: 16266787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.
    Dang CT
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):427-36. PubMed ID: 16503859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
    Nagykálnai T
    Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of taxanes in breast cancer chemotherapy: what's new 15 years after?].
    Herceg D; Vrbanec D
    Lijec Vjesn; 2009; 131(5-6):133-41. PubMed ID: 19642533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
    Bria E; Nistico C; Cuppone F; Carlini P; Ciccarese M; Milella M; Natoli G; Terzoli E; Cognetti F; Giannarelli D
    Cancer; 2006 Jun; 106(11):2337-44. PubMed ID: 16649217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxanes in adjuvant breast cancer setting: which standard in Europe?
    Campone M; Fumoleau P; Bourbouloux E; Kerbrat P; Roché H
    Crit Rev Oncol Hematol; 2005 Sep; 55(3):167-75. PubMed ID: 16039867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in systemic adjuvant therapy of early-stage breast cancer.
    Gradishar WJ; O'Regan RM
    Int J Clin Oncol; 2003 Aug; 8(4):239-47. PubMed ID: 12955580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxanes: impact on breast cancer therapy.
    Bachegowda LS; Makower DF; Sparano JA
    Anticancer Drugs; 2014 May; 25(5):512-21. PubMed ID: 24552749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
    Ravdin PM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant taxanes: more to the story.
    Gajria D; Seidman A; Dang C
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S41-9. PubMed ID: 20805064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxanes in adjuvant and neoadjuvant therapies for breast cancer.
    O'Leary J; Volm M; Wasserheit C; Muggia F
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):23-7. PubMed ID: 9516599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
    Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
    Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current trends in pharmacotherapy of breast cancer].
    Boér K
    Orv Hetil; 2002 Apr; 143(14):725-30. PubMed ID: 11975393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg.
    Hudis C
    Clin Breast Cancer; 2002 Dec; 3(5):326-32. PubMed ID: 12533262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
    Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.